Skip to content

Antibiotics for acute bronchitis

Treatment of acute bronchitis in general practice: A double blind RCT to determine the effectiveness of 500 mg amoxycillin versus placebo in reducing the duration of cough and severity of symptoms

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12606000509561
Acronym
ABFAB
Enrollment
40
Registered
2006-12-07
Start date
2005-07-26
Completion date
2007-07-10
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Acute bronchitis is the 5th most frequent reason to visit a general practitioner (GP), often leading to an antibiotic prescription even though guidelines advise that the infective organism is usually viral. Patient factors are partially responsible for these prescriptions but research indicates that GPs are inconsistent in their labelling of acute bronchitis and may feel the need to use antibiotics “just in case”. Studies indicate that, overall, patients with acute bronchitis may experience only a marginal benefit from antibiotic treatment, and this benefit may be offset by potential side effects. A recent Cochrane systematic review suggests that some patients may benefit from antibiotics. Based on clinical symptoms, signs and investigations, we think there may be two groups of patients with acute bronchitis - ‘uncomplicated’ and ‘complicated’- the former not requiring antibiotics and the latter, associated with poorer outcomes, who might benefit from their use. By identifying those sub-groups, GPs could be more certain about who to treat (and therefore who not to treat) leading to more rational and cost effective prescribing without compromising patient care. This is a double blind study which means that the patients have been randomly assigned to recieve either amoxycillin or placebo capsules for 6 days, and neither the patients nor the physicians or trial staff know which treatment has been allocated until database close.

Interventions

500 mg amoxycillin capsules. Oral dose taken three times a day for 6 days.

Sponsors

University of Adelaide
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1) presenting with an acute cough of less than 14 days, 2) at least one other symptom of a respiratory tract infection (sputum production, dyspnoea, wheeze, chest discomfort/pain), 3) at least one 'complicated' acute bronchitis sign (pulse rate >100, respiratory rate >25, oral temperature >38ºC, abnormal chest signs, age >55, confined to bed/very unwell, co-morbidity), 4) have read the patient information sheet and provided written consent, 5) able and willing to follow study requirements.

Exclusion criteria

1) a concurrent chronic respiratory illness that requires ongoing treatment, 2) antibiotics in the previous 3 weeks, 3) immunocompromised, 4) allergic to amoxycillin, penicillin, cephalospirins or beta-lactams, 5) lactose intolerant, 6) community acquired pneumonia, 7) bordatella pertussis.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026